Interview with Dr. David Yang, President, MicroConstants China
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Address: Suite 1-201, Building 18
99 Kechuang 14th Street
BDA, Beijing 101111
P.R.China
Tel: +86 (10) 59776728
Web: http://www.microconstants.com.cn/
MicroConstants China is a Contract Research Organization (CRO) that provides premier quality bioanalytical services, integrated clinical trial management services，IND-enabling drug metabolism (DMPK) assays, pharmacokinetic analysis, ELISA immunoassay, biomarker analysis, and quality system consulting to pharmaceutical/biotech companies and research institutes worldwide. Our in-house OECD GLP compliant bioanalytical laboratory specializes in method development, method validation, and sample analysis of small molecules, proteins, and peptides using LC/MS/MS, HPLC/UV, and ELISA for preclinical and clinical PK samples.
Our mission is to provide GLP/GCP compliant preclinical and clinical contract service in China to meet global product registration requirement.
Our goal is to conduct contract research service according to global recognized quality standards to ensure data integrity, accuracy, traceability and safety. Through vigorous audit of data, qualification and training of our partnering clinical site, open communication and quick resolve of our clients’ concern, we expedite our clients drug development process by providing data that meet various regulatory agencies requirement.
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Hooker Cockram is a well established company with an, impressive and rich history. Could you give us some background on both your operations in Australia and your operations in China…
Venturepharm is the most diversified company we’ve seen, throughout many verticals, taking a full-service plus model from venture capital, merchant banking, CRO, CMO, CSO, compound partnering to royalty sharing. That’s…
Could you please introduce the history and main characteristics of Biotech Pharmaceutical? Biotech Pharmaceutical was established in the year 2000, so we are a relatively young company for biopharmaceutical products…
You’ve run a number of life sciences companies now, but before that you started Telephia, an information services provider to the wireless industry. How did you make the jump to…
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
You have had significant experience at GSK and Pfizer, and also at Frontage Labs doing more entrepreneurial work. What ultimately brought you to Covance? I worked in Big Pharma for…
Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations, making it more convenient…
Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you…
In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re…
What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the late 1980s that there…
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps…
See our Cookie Privacy Policy Here
